Eltrombopag with gemcitabine-based chemotherapy in patients with advanced solid tumors: a randomized phase I study

Preventing chemotherapy-induced thrombocytopenia could avoid chemotherapy dose reductions and delays. The safety and maximum tolerated dose of eltrombopag, an oral thrombopoietin receptor agonist, with gemcitabine-based therapy was evaluated. Patients with advanced solid tumors and platelets ≤300 × ...

Descripción completa

Detalles Bibliográficos
Autores principales: Winer, Eric S, Safran, Howard, Karaszewska, Boguslawa, Richards, Donald A, Hartner, Lee, Forget, Frederic, Ramlau, Rodryg, Kumar, Kirushna, Mayer, Bhabita, Johnson, Brendan M, Messam, Conrad A, Mostafa Kamel, Yasser
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2015
Materias:
Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4312114/
https://www.ncbi.nlm.nih.gov/pubmed/25165041
http://dx.doi.org/10.1002/cam4.326

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4312114/
https://www.ncbi.nlm.nih.gov/pubmed/25165041
http://dx.doi.org/10.1002/cam4.326

Ejemplares similares